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EV ARRAY 
High-throughput Multiplexed Phenotyping of Extracellular Vesicles 
All living cells produce extracellular vesicles 
(EVs), which are nano-sized compart-
ments. They are considered as a pivotal 
part of the intercellular environment and act 
as important players in cell-to-cell 
communication. The fact, that EVs are 
involved in the development and progress-
sion of several diseases, has formed the 
basis for the use of EV analyses in a clinical 
setting and envisions a great potential 
for using EVs as disease-related 
biomarkers. 
EVs are a heterogeneous population of 
membrane -enclosed vesicles that can be 
divided into a number of subpopulations 
based on specific characteristics such as 
size, biogenesis, cellular origin, protein 
composition, and biological function. The 
two major subtypes of EVs are exosomes 
and microvesicles. 
Extracellular Vesicles 
The diagnostic power of the EVs to identify lung cancer 
patients can be visualized by the receiver operating 
characteristics (ROC), which shows the models’ 
sensitivity, specificity and accuracy. The data presented 
was obtained by analyzing EVs from 10 µL of plasma 
from 109 lung cancer patients (non-small cell lung 
cancer, NSCLC) together with 110 lung diseased 
patients (non-cancerous). A panel of 37 different EV 
markers were analyzed simultaneously and a 
multivariate data analysis was performed. Using the 
results from 30 of the variables it was possible to 
distinguish lung cancer patients from other lung 
diseased patients with a specificity of 79% and a 
sensitivity of 73% with an accuracy of 76%. 
Prognostic biomarkers are needed to improve patient selection 
for optimal treatment. We have evaluated EVs as a prognostic 
biomarker in NSCLC analyzing EVs in plasma from 276 NSCLC 
patients using the EV Array. Several markers were found to 
correlate to the overall survival (OS) of the patients. As shown on 
the survival curve, patients with CD171 positive EVs (blue curve) 
had a better overall survival with a 9.5 months longer median 
survival compared to patients without CD171 on their EVs (yellow 
curve). 
Other markers, as e.g. EGFR and NY-ESO-1, were found to 
influence the overall survival in a concentration-dependent 
manner. Patients with high levels of EVs positive for any one of 
these markers were found have a significantly lower mortality rate, 
with up to 4.6-times for EGFR. This indicates that high levels of 
specific EVs are protecting the patients against the cancer. 
Diagnostic and Prognostic Tool for Lung Cancer (NSCLC) 
Step 1: The EV Array is composed of different capture antibodies printed on a micro -array 
slide. 
 
Step 2: 10-100 µL plasma or other body fluids (urine, saliva, BALF, etc.) are applied in a 96-well 
setup and incubated 2 hours to overnight. 
 
Step 3: The EVs are detected with a cocktail of biotinylated antibodies. 
 
Step 4/5: The presence and thereby phenotype of EVs is visualized after incubation with 
Cy5-labeled Streptavidin using a fluorescence scanner. 
Principle of the Extracellular Vesicle Array (EV Array) 
Development Phase / Current state 
The current stage of the EV Array technology is a fully developed analysis 
optimized for a small-to-medium laboratory research scale. Several studies has 
demonstrated the EV Array efficiency in detecting cancers, lung-related diseases 
(pneumonia, COPD), venous thrombosis, multiple sclerosis and malaria.  
Technology Description / Technology Summary 
The EV Array is based on the technology of protein microarray and allows for the detection and phenotyping of EVs from unpurified starting material in a high-throughput manner. The technology was 
developed to perform multiplexed phenotyping of EVs in an open platform. The EV Array has been optimized for plasma, but can analyze urine, saliva, ascites, bone marrow, and cerebrospinal-, synovial- and 
bronchoalveolar fluids as well. 
Value proposition / USP 
EV Array is an unique biomarker platform that can exploit the 
intercellular trafficking in various biofluids to provide a non-invasive 
method for diagnostics and prognostics. 
Business Opportunity / Objective / Commercial Perspectives 
The apparent role of EVs in a vast number of biological processes, forms the basis of extending EV analysis beyond basic research 
and into clinical and therapeutic context. The applications of this type of analysis include the areas of diagnostics and prognostics, as 
well as drug therapy, regenerative medicine, and vaccines. The analysis of EVs could be incorporated as a screening tool and applied 
to confirm a diagnosis. Furthermore, the EV Array analysis has the potential to become an element in treatment surveillance and 
companion diagnostics. 
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The Inventors 
A. Barcoded microarray glass slides (7.5 x 2.5cm) printed in a 21-well setup. 
B. Printed slides are placed in multiwell-cassettes for either one glass slide (up 
to 21 samples) or four glass slides (up to 84 samples). 
C. The procedure is validated by a quality control of the printed spots, which in-
cludes positive and negative controls. 
D. Scanning after capture and detection of EVs can be performed on a normal 
laboratory fluorescence scanner or on a specialized microarray scanner for 
maximum sensitivity. 
EV Array in Practice 
